<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are associated with an atherogenic <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> profile </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the role of visceral and subcutaneous fat depots, independent of BMI, on the <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 382 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> underwent abdominal computed tomography to evaluate subcutaneous (SAT) and visceral adipose tissue (VAT) distribution and had anthropometric measurements to determine BMI and waist and hip circumference </plain></SENT>
<SENT sid="3" pm="."><plain>Fasting blood was obtained for <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> particle number and size using nuclear magnetic resonance spectroscopy </plain></SENT>
<SENT sid="4" pm="."><plain>The relationship of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> particle number and size with BMI, SAT, and VAT was examined using multivariable regression models adjusted for age, sex, <z:mp ids='MP_0002055'>diabetes</z:mp> therapy, duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, smoking, <z:chebi fb="0" ids="35664">statin</z:chebi> use, and A1C levels </plain></SENT>
<SENT sid="5" pm="."><plain>The relation of VAT to <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> particle number and size was further evaluated after the addition of BMI, BMI plus SAT, or BMI plus homeostatis is model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR) to the model </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: VAT was positively related to <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle number (P &lt; 0.0001), <z:chebi fb="15" ids="39026">LDL</z:chebi> particle number (P &lt; 0.01), and <z:chebi fb="1" ids="39027">VLDL</z:chebi> size (P &lt; 0.0001) and negatively related to <z:chebi fb="15" ids="39026">LDL</z:chebi> size (P &lt; 0.0001) and <z:chebi fb="17" ids="39025">HDL</z:chebi> size (P &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>These relationships remained unchanged after addition of BMI and SAT to the model </plain></SENT>
<SENT sid="8" pm="."><plain>After addition of HOMA-IR, VAT remained positively related to <z:chebi fb="1" ids="39027">VLDL</z:chebi> particle number (P &lt; 0.0001) and size (P &lt; 0.01) and negatively related to <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="17" ids="39025">HDL</z:chebi> particle size (P &lt; 0.0001 for both comparisons) </plain></SENT>
<SENT sid="9" pm="."><plain>Neither BMI nor SAT was independently related to <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> parameters </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, higher VAT independent of BMI was associated with higher <z:chebi fb="1" ids="39027">VLDL</z:chebi> and <z:chebi fb="15" ids="39026">LDL</z:chebi> particle number, larger <z:chebi fb="1" ids="39027">VLDL</z:chebi> particles, and smaller <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="17" ids="39025">HDL</z:chebi> particles </plain></SENT>
<SENT sid="11" pm="."><plain>This <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> pattern has been associated with increased risk for <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
</text></document>